Ekso Bionics’ Stockholders Elect Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors
December 30 2020 - 8:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced the election of Mary Ann Cloyd and
Rhonda A. Wallen to its Board of Directors by vote of stockholders
at its 2020 Annual Meeting on December 29, 2020, effective
immediately.
“We are excited to welcome Mary Ann and Rhonda
to our Board, both of whom add decades of business and healthcare
knowledge,” said Jack Peurach, President and Chief Executive
Officer of Ekso Bionics. “They are industry veterans with extensive
experience serving on boards and overseeing corporate strategies.
We are confident they will provide valuable perspectives as we
continue to fulfill our mission to amplify human motion across
medical and industrial verticals with advanced robotics.”
Ms. Cloyd brings nearly 40 years of experience
in public accounting and advisory, corporate governance, and risk
management and oversight. She currently serves on the Boards of
Bellerophon Therapeutics, Fresh Del Monte Produce, and NCMIC Group.
Active in professional and community organizations, Ms. Cloyd is
also on the Board of the Geffen Playhouse and the Advisory Board of
the UCLA Iris Cantor Women’s Center. From 1990 until her retirement
in 2015, Ms. Cloyd was a senior partner at PricewaterhouseCoopers
LLP (“PwC”), where she served multinational corporate clients in a
variety of industries, including the biotechnology and
pharmaceutical industries. She was the leader of the PwC Center for
Board Governance from 2012 to 2015 and has also served on both
PwC’s Global and U.S. Boards. Ms. Cloyd also served on the Board of
Trustees of the PwC Charitable Foundation, and previously served as
President of the Foundation.
“I am honored to join Ekso Bionics’ Board and to
be part of such an innovative company that is elevating the
standard of care for medical patients and improving industrial
workforce productivity,” said Ms. Cloyd. “I look forward to
providing my industry and advisory expertise to strengthen customer
and stockholder value.”
Ms. Wallen has 25 years of experience working
within the life sciences and healthcare industries. With a focus on
business management and corporate development, Ms. Wallen brings
board oversight as well as investment expertise. Currently VP
Marketing & Corporate Development of SteriLumen, the medical
division of AppliedUV, she was most recently the Head of Corporate
Development for Terumo BCT, the biomedical division of Terumo
Corporation. Previously, Ms. Wallen served as the Chief Operating
Officer of Andarix Pharmaceuticals. Also, during this time as a
consultant with Cygnet Venture Management, she held senior level
business development and marketing positions where she worked with
life science CEOs and founders to validate the strategic direction
of emerging growth companies, define key milestones and complete
corporate financings. Ms. Wallen is a Director of Boulder Community
Health, and a Board Advisor to venture-backed companies, DrugViu
and Aromyx.
“I am thrilled to join the Board of Ekso
Bionics, a company that provides unique medical and industrial
solutions,” said Ms. Wallen. “I recognize the daily value that Ekso
Bionics creates with its cutting-edge EksoNR and EVO exoskeletons,
and am excited for the Company’s future in bringing differentiated
and advanced robotics to recovering stroke patients as well as
industrial clients.”
About Ekso
Bionics® Ekso Bionics® is a
leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical and industrial applications. Founded in
2005, the Company continues to build upon its industry-leading
expertise to design some of the most cutting-edge, innovative
wearable robots available on the market. Ekso Bionics is the only
exoskeleton company to offer technologies that range from helping
those with paralysis to stand up and walk, to enhancing human
capabilities on job sites across the globe. The Company is
headquartered in the San Francisco Bay Area and is listed on the
Nasdaq Capital Market under the symbol “EKSO.” For more
information,
visit: www.eksobionics.com or follow
@EksoBionics on Twitter.
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024